US approves updated Pfizer, Moderna shots targeting Omicron / Photo: © AFP/File
SCS
0.2300
The Fort Worth Press - US approves updated Pfizer, Moderna shots targeting Omicron
USD
-
AED 3.673042
AFN 67.503991
ALL 94.250403
AMD 389.764479
ANG 1.803631
AOA 913.000367
ARS 1003.850089
AUD 1.537516
AWG 1.8025
AZN 1.70397
BAM 1.878951
BBD 2.020559
BDT 119.587668
BGN 1.87774
BHD 0.37683
BIF 2895
BMD 1
BND 1.348865
BOB 6.915269
BRL 5.801041
BSD 1.000769
BTN 84.471911
BWP 13.672019
BYN 3.275129
BYR 19600
BZD 2.017245
CAD 1.39845
CDF 2871.000362
CHF 0.893615
CLF 0.035758
CLP 986.680396
CNY 7.243041
CNH 7.25914
COP 4420.25
CRC 509.751177
CUC 1
CUP 26.5
CVE 106.303894
CZK 24.326204
DJF 177.720393
DKK 7.157904
DOP 60.450393
DZD 134.27504
EGP 49.650175
ERN 15
ETB 123.010392
EUR 0.95985
FJD 2.27595
FKP 0.789317
GBP 0.798085
GEL 2.740391
GGP 0.789317
GHS 15.803856
GIP 0.789317
GMD 71.000355
GNF 8631.000355
GTQ 7.725046
GYD 209.369911
HKD 7.78445
HNL 25.230388
HRK 7.133259
HTG 131.367086
HUF 395.010388
IDR 15943.55
ILS 3.70204
IMP 0.789317
INR 84.43625
IQD 1310.5
IRR 42075.000352
ISK 139.680386
JEP 0.789317
JMD 159.42934
JOD 0.709104
JPY 154.77504
KES 129.503801
KGS 86.503799
KHR 4051.00035
KMF 472.503794
KPW 899.999621
KRW 1404.510383
KWD 0.30785
KYD 0.834002
KZT 499.690168
LAK 21960.000349
LBP 89600.000349
LKR 291.267173
LRD 180.000348
LSL 18.130381
LTL 2.95274
LVL 0.60489
LYD 4.885039
MAD 10.074504
MDL 18.253698
MGA 4670.000347
MKD 59.076288
MMK 3247.960992
MNT 3397.999946
MOP 8.023845
MRU 39.905039
MUR 46.850378
MVR 15.460378
MWK 1735.000345
MXN 20.428404
MYR 4.468039
MZN 63.910377
NAD 18.130377
NGN 1696.703725
NIO 36.750377
NOK 11.072604
NPR 135.155518
NZD 1.714237
OMR 0.385003
PAB 1.000793
PEN 3.794039
PGK 4.02575
PHP 58.939038
PKR 277.803701
PLN 4.163902
PYG 7812.469978
QAR 3.640504
RON 4.776604
RSD 112.339038
RUB 104.308748
RWF 1370
SAR 3.754663
SBD 8.383555
SCR 14.282217
SDG 601.503676
SEK 11.036204
SGD 1.346504
SHP 0.789317
SLE 22.730371
SLL 20969.504736
SOS 571.503662
SRD 35.494038
STD 20697.981008
SVC 8.756761
SYP 2512.529858
SZL 18.130369
THB 34.470369
TJS 10.658046
TMT 3.5
TND 3.180504
TOP 2.342104
TRY 34.553704
TTD 6.797003
TWD 32.583504
TZS 2660.000335
UAH 41.401274
UGX 3697.761553
UYU 42.558915
UZS 12830.000334
VES 46.55914
VND 25419
VUV 118.722009
WST 2.791591
XAF 630.19767
XAG 0.031938
XAU 0.000369
XCD 2.70255
XDR 0.761283
XOF 624.503595
XPF 114.875037
YER 249.925037
ZAR 18.09614
ZMK 9001.203587
ZMW 27.645705
ZWL 321.999592
- Wealthy nations offer $250 bn on climate but pressed for more
- COP29 draft deal proposes rich nations give $250 bn in climate finance
- Deadlocked COP29 awaits fresh draft deal on final day
- Global stocks mostly cheer Nvidia results as bitcoin gains
- Israel strikes kill 52 in Lebanon as Hezbollah targets south Israel
- Five tourists dead after suspected tainted alcohol poisoning in Laos
- Palestinians welcome ICC arrest warrants for Israeli officials
- Senegal ruling party wins parliamentary majority: provisional results
- Fiji's Loganimasi in for banned Radradra against Ireland
- New proposal awaited in Baku on climate finance deal
US approves updated Pfizer, Moderna shots targeting Omicron
US health officials on Wednesday authorized updated Covid-19 vaccinations by Moderna and Pfizer-BioNTech that specifically target the latest strains of the Omicron variant, with the goal of jump-starting a new booster campaign.
The two updated booster shots aimed at providing "better protection against Covid-19 caused by the Omicron variant" are approved for people age 12 and above for the Pfizer shot and 18 and older for Moderna, the Food and Drug Administration (FDA) said in a statement.
This new generation of anti-Covid vaccines targets both the original strain of coronavirus and the BA.4 and BA.5 lineages, the subvariants of Omicron that are causing the most cases in the United States and which the FDA predicts will circulate in the coming months.
Earlier this summer the US health department announced it had purchased 105 million doses from Pfizer and 66 million from Moderna for use over the fall and winter.
The vaccines have yet to be recommended by the Centers for Disease Control and Prevention, the nation's health protection agency. But an independent panel of experts is scheduled to be convened by the CDC on Thursday to discuss the updates.
CDC director Rochelle Walensky will be in charge of giving the final green light.
The new versions of the vaccines could potentially be available in the United States as early as next week.
"Receiving a booster that specifically targets the Omicron BA.4/.5 variant, currently the most prevalent strain of SARS-CoV-2, is an important public health measure that people can take to help protect themselves, especially as we head into a season filled with indoor gatherings," Moderna chief executive Stephane Bancel said in a statement.
The vaccines currently in circulation target the initial strain of the virus that first appeared in Wuhan, China. But they have gradually proven to be less effective against the variants that have appeared over time, due to rapid evolution of the virus.
In contrast to the Alpha and Delta variants, which eventually waned, Omicron and its subvariants have come to dominate infections worldwide in 2022.
Pfizer and Moderna have also filed for approval of their updated vaccines with the European Medicines Agency.
T.M.Dan--TFWP
